Deucravacitinib Therapeutic Cheat Sheet
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt …
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt … 
Sarecycline is a third-generation, narrow-spectrum tetracycline developed specifically for the treatment of acne vulgaris. It is distinguished by its weight-based once-daily dosing, favorable side effect profile, and relative microbiome-sparing compared with older tetracyclines. We continue our series, Therapeutic Cheat Sheet, with a closer look at Sarecycline.
� … 
Cyclophosphamide, an alkylating agent introduced in the 1950s, has long served as a cornerstone therapy in rheumatology and oncology for its potent cytotoxic and immunosuppressive effects. In dermatology, it has been employed as a rescue agent for severe, refractory autoimmune and inflammatory skin diseases, particularly those associated with systemic connective tissue disorders. Its role spans co … 
Propranolol, a nonselective β-adrenergic blocker introduced in the 1960s, remains a cornerstone therapy in cardiology for hypertension, angina, and migraine prophylaxis. It has since gained transformative use in dermatology following the serendipitous discovery of its efficacy in infantile hemangiomas (IH), becoming the first FDA-approved systemic therapy for proliferating IH in 2014 given its va … 
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory …